Locally Advanced Breast Cancer Clinical Trial
Official title:
Influence of Intermittent Fasting on Locally Advanced Breast Cancer Patients: a Prospective Randomized Controlled Trial
NCT number | NCT06174259 |
Other study ID # | 1998DRXVTF |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | June 1, 2023 |
Est. completion date | June 1, 2025 |
Breast cancer is the most common cancer type among women in Egypt and world. Preclinical studies show fasting reduces growth factors and modulates nutrient sensing systems, protecting normal cells against chemotherapy. However, cancer cells are not protected due to Differential Stress Resistance (DSR), making them more vulnerable to chemotherapeutics. This study aims to evaluate intermittent fasting impact on neoadjuvant chemotherapy in breast cancer patients.
Status | Recruiting |
Enrollment | 66 |
Est. completion date | June 1, 2025 |
Est. primary completion date | June 1, 2024 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Female patients with stage II or III (cT1cN+ or =T2 any cN, cM0) breast cancer. - Planned to receive standard neoadjuvant chemotherapy. - Measurable disease (breast and/or lymph nodes). - WHO performance status 0-2. - Being overweight (BMI: 25-29.9 kg/m2) or obese (BMI: =30 kg/m2). - Adequate bone marrow function : white blood cells (WBCs) =3.0 x 109/l, neutrophils =1.5 x 109/l, platelets =100 x 109/l - Adequate liver function: bilirubin =1.5 x upper limit of normal (UNL) range, ALAT and/or ASAT =2.5 x UNL, Alkaline Phosphatase =5 x UNL - Adequate renal function: the calculated creatinine clearance should be =50 mL/min - Patients must be accessible for treatment and follow-up Exclusion Criteria: - Serious diseases such as recent myocardial infarction, clinical signs of cardiac failure or clinically significant arrhythmias - Diabetes Mellitus. - Pregnancy or lactating - Any metabolic disorders that may affect gluconeogenesis or adaptation to fasting periods. - Previous malignancy. - Using weight loss medication. |
Country | Name | City | State |
---|---|---|---|
Egypt | Menoufia university | Shibin Al Kawm | Menoufia |
Lead Sponsor | Collaborator |
---|---|
Menoufia University |
Egypt,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | pathological response rate | Assessment of pathological response using the Miller-Payne grading system; it is a grading system from 1-5 with 5 is the best response | 6months | |
Secondary | The percentage of patients with grade III/IV toxicity | Common Terminology Criteria for Adverse Events (CTCAE) v5.0 | 6 months | |
Secondary | Grade I/II side effects of chemotherapy | Common Terminology Criteria for Adverse Events (CTCAE) v5.0 | 6 months | |
Secondary | Clinical response | Radiological before and after the NACT (neoadjuvant chemotherapy) using Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 | 6months | |
Secondary | Body composition changes (fat, muscles, water) | using Bioimpedance analysis (BIA) assessment before, 3months and at the end of NACT | 6 months | |
Secondary | Inflammatory response to chemotherapy. | CRP level | 6 months | |
Secondary | Long term efficacy of treatment | (DFS, OS) | 5 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01048918 -
Characterization of Circulating Tumor Cells (CTC-s) in Patients With Locally Advanced or Metastatic Stage IV Breast Cancer
|
||
Recruiting |
NCT05383196 -
Onvansertib + Paclitaxel In TNBC
|
Phase 1/Phase 2 | |
Recruiting |
NCT05744375 -
Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab
|
Phase 2 | |
Terminated |
NCT01837563 -
Monitoring of Neoadjuvant Therapy in Locally-Advanced Breast Cancer
|
N/A | |
Recruiting |
NCT03978663 -
Three Fraction Radiation to Induce Immuno-Oncologic Response
|
N/A | |
Active, not recruiting |
NCT04352777 -
Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer
|
Phase 2 | |
Recruiting |
NCT06064812 -
A Phase I Clinical Trial of FWD1802 in Patients With ER+/HER2- BC.
|
Phase 1 | |
Recruiting |
NCT05963997 -
A Study of Samuraciclib and Elacestrant in Participants With Metastatic or Locally Advanced HR+/HER2-negative Breast Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT06080620 -
The Choice of Treatment Methods and Efficacy of LABC
|
N/A | |
Completed |
NCT05002868 -
Safety, Pharmacokinetics and Anti-tumor Activity of RP12146, in Patients With Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT02595762 -
A Study of Treatment Patterns and Outcomes in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced or Metastatic Breast Cancer
|
||
Active, not recruiting |
NCT02965950 -
The p53 Breast Cancer Trial
|
Phase 2 | |
Completed |
NCT01785992 -
A Study of the Safety and Effectiveness of Irosustat When Added to an AI in ER+ve Locally Advanced or Metastatic Breast Cancer.
|
Phase 2 | |
Completed |
NCT00764036 -
Study of Artesunate in Metastatic Breast Cancer
|
Phase 1 | |
Active, not recruiting |
NCT03685331 -
HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer
|
Phase 1 | |
Completed |
NCT05021900 -
Efficacy and Safety of Tenalisib (RP6530), a PI3K δ/γ and SIK3 Inhibitor, in Patients With Locally Advanced or Metastatic Breast Cancer
|
Phase 2 | |
Withdrawn |
NCT04088032 -
Neoadjuvant Study of Abemaciclib, Durvalumab, and an Aromatase Inhibitor Early Stage Breast Cancer
|
Early Phase 1 | |
Completed |
NCT00455273 -
Dynamic Breast MRI in Assessing Locally Advanced Breast Cancer
|
||
Terminated |
NCT04042051 -
Copanlisib in Combination With T-DM1 in Pretreated Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer
|
Phase 1 | |
Recruiting |
NCT05582499 -
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
|
Phase 1/Phase 2 |